Literature DB >> 16427984

Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection.

Chien-Chun Chiou1, Wen-Hung Chung, Shuen-Iu Hung, Li-Cheng Yang, Hong-Shang Hong.   

Abstract

Drug hypersensitivity syndrome (DHS) is an idiosyncratic and life-threatening adverse drug reaction characterized by skin rash and multiorgan involvement. In rare cases, fulminant type1 diabetes mellitus (DM) may develop after DHS. Among proposed pathogenesis, human herpesvirus 6 (HHV-6) infections may play a role in the development of DHS. We report a case of DHS associated with HHV-6 reactivation, complicated with a rare sequela of irreversible fulminant type 1 DM. No diabetes-related autoantibodies were detected. Early detection and intervention for this serious complication should be given in patients with DHS. Fulminant type1 DM associated with DHS is reviewed. The role of HHV-6 in DHS associated with fulminant type 1 DM is also discussed.

Entities:  

Mesh：

Year:  2006        PMID： 16427984     DOI： 10.1016/j.jaad.2005.03.057

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


  17 in total

1.  Pathogenesis of fulminant type 1 diabetes.

Authors:  Akihisa Imagawa; Toshiaki Hanafusa
Journal:  Rev Diabet Stud       Date:  2007-02-10

2.  Association of cytomegalovirus and other pathogens with frailty and diabetes mellitus, but not with cardiovascular disease and mortality in psycho-geriatric patients; a prospective cohort study.

Authors:  Michiel B Haeseker; Evelien Pijpers; Nicole Htm Dukers-Muijrers; Patty Nelemans; Christian Jpa Hoebe; Cathrien A Bruggeman; Annelies Verbon; Valère J Goossens
Journal:  Immun Ageing       Date:  2013-07-23       Impact factor: 6.400

Review 3.  Fever, rash, and systemic symptoms: understanding the role of virus and HLA in severe cutaneous drug allergy.

Authors:  Rebecca Pavlos; Simon Mallal; David Ostrov; Yuri Pompeu; Elizabeth Phillips
Journal:  J Allergy Clin Immunol Pract       Date:  2014 Jan-Feb

4.  Anti-Saccharomyces cerevisiae antibodies are frequent in type 1 diabetes.

Authors:  Wahiba Sakly; Amani Mankaï; Nabil Sakly; Yosra Thabet; Achouak Achour; Leila Ghedira-Besbes; Moncef Jeddi; Ibtissem Ghedira
Journal:  Endocr Pathol       Date:  2010-06       Impact factor: 3.943

5.  Drug Reaction, Eosinophilia and Systemic Symptoms (DRESS) syndrome secondary to allopurinol with early lymphadenopathy and symptom relapse.

Authors:  Rhiannon Turney; Jordan Peter Skittrall; Joseph Donovan; Daniel Agranoff
Journal:  BMJ Case Rep       Date:  2015-10-05

Review 6.  DIABETIC KETOACIDOSIS: A COMMON DEBUT OF DIABETES AMONG AFRICAN AMERICANS WITH TYPE 2 DIABETES.

Authors:  Priyathama Vellanki; Guillermo E Umpierrez
Journal:  Endocr Pract       Date:  2017-05-23       Impact factor: 3.443

Review 7.  Is the drug-induced hypersensitivity syndrome (DIHS) due to human herpesvirus 6 infection or to allergy-mediated viral reactivation? Report of a case and literature review.

Authors:  Ivan Gentile; Maria Talamo; Guglielmo Borgia
Journal:  BMC Infect Dis       Date:  2010-03-06       Impact factor: 3.090

Review 8.  Recent advances in the understanding of severe cutaneous adverse reactions.

Authors:  N R Adler; A K Aung; E N Ergen; J Trubiano; M S Y Goh; E J Phillips
Journal:  Br J Dermatol       Date:  2017-09-29       Impact factor: 9.302

9.  Minocycline-induced drug hypersensitivity syndrome followed by multiple autoimmune sequelae.

Authors:  Rebecca J Brown; Kristina I Rother; Henry Artman; Mary Gail Mercurio; Roger Wang; R John Looney; Edward W Cowen
Journal:  Arch Dermatol       Date:  2009-01

10.  Risk factors for sudden death and cardiac arrest at the onset of fulminant type 1 diabetes mellitus.

Authors:  Megu Yamaguchi Baden; Akihisa Imagawa; Hiromi Iwahashi; Iichiro Shimomura; Takuya Awata; Hiroshi Ikegami; Yasuko Uchigata; Haruhiko Osawa; Hiroshi Kajio; Eiji Kawasaki; Yumiko Kawabata; Akira Shimada; Kazuma Takahashi; Shoichiro Tanaka; Kazuki Yasuda; Hisafumi Yasuda; Tetsuro Kobayashi; Toshiaki Hanafusa
Journal:  Diabetol Int       Date:  2015-12-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.